Recruiting

CONFIRM: Magnetic Resonance Guided Radiation Therapy

This research is being done to determine the safety and feasibility of using a type of radiation guided by magnetic resonance imaging (MRI) and chemotherapy to treat patients with gastric and breast cancer. The name of the radiation machine involved in this study is the MRIdian Linear Accelerator.

ClinicalTrials.gov IDNCT04368702

PhaseNA

Enrollment70

SponsorBrigham and Women's Hospital

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Gastric Cancer, Invasive Breast Cancer, in Situ Breast Cancer, Mantle Cell Lymphoma, Larynx Cancer, Bladder Cancer

About this study

Interventions

Radiation: Viewray MRIdian® Linac — MR-image guided radiation will be administered per disease site standards.

Primary outcomes

Number of Patients and delivering MR-image guided radiation-Phase I (5 weeks)
Tumor Assessment with MR Guidance-Phase I (5 weeks)
Patient reported outcomes (PROMs) -Phase II (1 year)
1-year tumor control-Phase II (1 year)
Rate of Pathologic complete response-Gastric (1 year)

Eligibility information

Inclusion Criteria: * Participants must have histologically or cytologically confirmed malignancy requiring radiation * Age 18 years of older * ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A) * Ability to understand and the willingness to sign a written informed consent document. * Any further criteria listed in the specific disease site cohort Exclusion Criteria * History of allergic reactions attributed to gadolinium-based IV contrast \-- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility * Severe claustrophobia or anxiety * Participants who cannot undergo an MRI * Any other exclusion criteria listed in the specific disease site cohort

Study locations

Brigham & Women's Hospital, Boston, Massachusetts 02115 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.